Hematologic
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections (X4P-001-110)
- Details
ClinicalTrials.gov ID:
NCT06056297
Diagnosis Type:
NA
USOR Number:
- Address
,
P: